Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

B7

The B7 family constitutes a pivotal group of co-signaling molecules in immune regulation, encompassing members such as B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1), B7-DC (PD-L2), B7-H3 (CD276), B7-H4 (VTCN1), B7-H5 (HHLA2), B7-H6, and B7-H7. These molecules mediate activation or inhibitory signals by binding to CD28/CTLA-4, PD-1, or undefined receptors, thereby regulating T cell activation, proliferation, and immune tolerance. The B7 family plays a critical role in infection, autoimmunity, and tumor immune evasion, and has emerged as a significant therapeutic target for immune checkpoint inhibitors, CAR-T therapies, and bispecific antibodies.

Enoblituzumab
T9901A-0021353485-38-7
Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC).
  • $195
In Stock
Size
QTY
Omburtamab
T782741895083-75-6
Omburtamab is a monoclonal antibody targeting CD276, often conjugated to 131 radioactive iodine ions, used for radioimmuno positron emission tomography studies.
  • $213
In Stock
Size
QTY
FDW028
T778092768426-49-7
FDW028 is a selective and potent fucosyltransferase 8 (FUT8) inhibitor with anti-tumor activity that drives B7-H3 lysosomal degradation via defucosylation and CMA pathways. FUT8 can be used to study metastatic colorectal cancer (mCRC).
  • $64
In Stock
Size
QTY
Mirzotamab
T779092229859-11-2
Mirzotamab is an IgG1κ antibody targeting CD276 B7-H3 and is the naked antibody to Mirzotamab clezutoclax, consisting of 1320 amino acids.
  • $208
In Stock
Size
QTY
Puxitatug
T813452760250-47-1
Puxitatug (INT-016) is a humanised monoclonal antibody targeting VTCN1 B7H4, commonly used as the targeting component of the antibody-drug conjugate (ADC) Puxitatug samrotecan, delivering the drug specifically to cancer cells expressing B7-H4.
  • $247
In Stock
Size
QTY
Ifinatamab
T782922484870-90-6
Ifinatamab is a humanised monoclonal immunoglobulin that targets and inhibits the B7-H3 protein. Ifinatamab can be used to synthesise the ADC drug Ifinatamab deruxtecan for the treatment of small cell lung cancer (SCLC).
  • $489
In Stock
Size
QTY